shuman@medicine.ucsf.edu
(415) 476-2125 (voice)
(415) 514-4661 (fax)

Box 1270, UCSF; San Francisco, CA 94143-1270

additional websites:

Shuman Lab Website

University of Wisconsin, Madison Madison, WI, B.S., 1962, Philosophy/Chemistry
University of PA, Philadelphia Philadelphia, PA, Biology
Thomas Jefferson Medical College Philadelphia, PA, M.D., 1967, Medicine

Cohen RL, X P Xi, CW Crowley, BK Lucas, AD Levinson, and MA Shuman. (1991). Selective inhibition of the urokinase receptor: Effects on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 78:479-487.

Crowley, C.W., R.L. Cohen, B.K. Lucas, G. Liu, M.A. Shuman, and A.D. Levinson. (1993). Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA. 90:5021-25.

Bianchi, E., R.L. Cohen, A.T. Thor, R.F. Todd III, I.F. Mizukami, D.A. Lawrence, B.M. Ljung, M.A Shuman, HS Smith. (1994). The urokinase receptor in expressed in invasive breast cancer but not in normal breast tissue. Cancer Research 54: 861-6.

Liu, G., M.A. Shuman, R.L. Cohen. (1995). Co-espression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of clutured lung cancer cells. Int. J. Cancer 60: 501-6.

Banchi, E., R.L. Cohen, A. Dai, A.T. Thor, M.A. Shuman, and H.S. Smith. (1995). Immunohistochemical localization of thethe plasminogen activator inhibitor-1 in breast cancer. International J. Cancer, 60(5): 597-603.

Melnyk, O., M.A. Shuman, and K.J. Kim. (1996). Vascular endothelial growth factor (VEGF) promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Research. 56:921-924, 1996.

Min, H.Y., L.V. Doyle, C.R. Vitt, C.L. Zandonella, J.R. Stratton-Thomas, M.A. Shuman, S. Rosenberg. (1996). Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Research 56:2428-2433.

Evans, C.P., Elfman, F., Parangi, S., Conn, M. Cunha, G. and Shuman, M.A. (1997). Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Research, 57(16):3594-9.

Shaham, S., M.A. Shuman, I. Herskowitz. (1998). Death-defying yeast identify novel apoptosis genes. Cell, 92(4): 425-7.

Takeuchi, T., M.A. Shuman, C.S. Craik. (1999). Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biologic al processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA., 96:11054-61.

Melnyk, O., Zimmerman. M., Kim, K.J., and M.A. Shuman. (1999) Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. Journal of Urology, 161:960-3.

Bok, R.A., S. Halabi, D.T. Fei, C.R. Rodriguez, D.F. Hayes, N.J. Vogelzang, P. Kantoff, M.A. Shuman, and E.J. Small. (2000). Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-Refractory Prostate Cancer Patients. Cancer Res. 61:2533-36.

Rubenstein, J.L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D., and Shuman, M.A. 2000. Anti-VEGF Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption. Neoplasia. 2(4) 306-314.

Elfman, F., R. Bok, M. Conn, M.A. Shuman, and G.Cunha. (2001). Urokinase plasinogen activator amino-teminal peptides inhibit development of the rat ventral prostate. Differentiation 69:108-120.

Bok, R.A., Halabi, S., Fei, D.T., Rodriquez, C.R., Hayes, D.F., Vogelzang, N.J., Kantoff, P., Shuman, M.A., and Small, E.J. (2001) Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-Refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study. Cancer Res. 61:2533-36.

Swanson,MG, Bok, RA, Shuman, MA, Vigneron, DB, Kurhanewicz, J. 1H HR-MAS spectroscopic investigation of prostate cancer development and progression in the TRAMP mouse. Proc .ISMRM, 10:2174 (2002).

Bhatt AS, Takeuchi T, Ylstra B, Ginzinger D, Albertson D, Shuman MA, Craik CS. (2003) Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem. 384(2): 257-66.

Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood.101 (2):466-8.

Bok RA, Hansell EJ, Nguyen TP, Greenberg NM, McKerrow,JH, Shuman MA. (2003) Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer and Prostate Diseases. 6:272-280.

Tindall D, Horne FM, Hruszkewycz A, Mohla S, Shuman M, Wang Z, Kantoff P. (2004) Symposium on androgen action in prostate cancer. Cancer Research 64 (19): 7178-80.

Rubenstein J, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006; 107(9) : 3716-23, 2006.

Chan JM, Feraco A, Shuman M, Hernandez-Diaz S. The epidemiology of prostate cancer-- with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am. 2006; 20(4): 797-809.

Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008; 26(1): 96-105.

7/21/08